Related Experiment Videos
[Histoculture drug response assay on non-small cell lung cancer]
T Yoshimasu1, S Oura, S Maebeya
1Dept. of Thoracic and Cardiovascular Surgery, Wakayama Medical College.
Abstract:
We examined the chemosensitivity of non-small cell lung cancer (NSCLC) tissues to CDDP, 5-FU, ADM, MMC, ETP and SN38 using histoculture drug response assay (HDRA). One-hundred and thirty surgical specimens from NSCLC patients who were not given preoperative chemotherapy were used. The inhibition indexes of CDDP, 5-FU, MMC, ADM, ETP and SN38 were 39.1 +/- 18.2%, 48.0 +/- 19.7%, 63.3 +/- 17.7%, 47.6 +/- 22.0%, 36.9 +/- 21.1%, and 37.9 +/- 25.2%, respectively. Inhibition indexes were above the cutoff level, i.e., 'judged sensitive,' in 40 cases (31.3%) for CDDP, 34 cases (27.4%) for 5-FU, 54 cases (44.3%) for MMC, 36 cases (33.0%) for ADM, 29 cases (29.8%) for ETP, and 34 cases (37.4%) for SN38, respectively. In almost one-third of patients, the inhibition indexes of all drugs were under cutoff levels. Correlations between in vitro chemosensitivity data and patient responses to chemotherapy were obtained from 16 evaluable patients, and a 44.4% true positive rate and a 100% true negative rate were observed. Our results with HDRA for NSCLC showed a high incidence of intrinsic multidrug resistance. HDRA may help doctors to avoid non-effective chemotherapy for NSCLC patients.
Insights
Histoculture drug response assay (HDRA) assessed non-small cell lung cancer (NSCLC) chemosensitivity. Results indicate high intrinsic multidrug resistance, suggesting HDRA can guide effective chemotherapy selection for NSCLC patients.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Non-small cell lung cancer (NSCLC) presents a significant challenge due to intrinsic multidrug resistance.
- Predicting patient response to chemotherapy is crucial for effective treatment planning.
Purpose of the Study:
- To evaluate the chemosensitivity of NSCLC tissues to various chemotherapeutic agents using the histoculture drug response assay (HDRA).
- To determine the incidence of intrinsic multidrug resistance in NSCLC.
- To assess the correlation between in vitro drug sensitivity and clinical patient response.
Main Methods:
- The study utilized the histoculture drug response assay (HDRA) on 130 surgical specimens from NSCLC patients.
- Chemosensitivity was tested against cisplatin (CDDP), 5-fluorouracil (5-FU), doxorubicin (ADM), mitomycin C (MMC), etoposide (ETP), and SN38.
- Inhibition indexes were calculated, and sensitivity was defined by a cutoff level.
Main Results:
- Significant variations in drug inhibition indexes were observed across the tested agents.
- Mitomycin C (MMC) showed the highest inhibition index (63.3%), with 44.3% of cases judged sensitive.
- A substantial proportion of patients (nearly one-third) exhibited resistance to all tested drugs.
- Correlation analysis in 16 patients showed a 44.4% true positive and 100% true negative rate for predicting response.
Conclusions:
- The HDRA revealed a high prevalence of intrinsic multidrug resistance in NSCLC.
- HDRA shows potential as a tool to personalize chemotherapy by identifying non-effective treatments for NSCLC patients.
- This assay may improve treatment outcomes by guiding clinicians toward more effective therapeutic strategies.